Compare Freeport-McMoRan Inc (FCX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Recursion Pharmaceuticals Inc — how do they compare? Freeport-McMoRan Inc trades at $73.69 (market cap $102.16B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Freeport-McMoRan Inc is far larger — about 47.7× Recursion Pharmaceuticals Inc's market cap, and Freeport-McMoRan Inc pays a 0.84% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 69 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| FCX | RXRX | |
|---|---|---|
Market Cap | $102.16B | $2.14B |
Volume | 9,047,971 | 30,789,535 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $6.79 |
52-Week Low | $38.65 | $2.84 |
Typical Hold Time | 69 Days | 23 Days |
Enterprise Value | $108.44B | $1.66B |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $71.13, down 1.02% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.68 exceeding the $0.60 estimate. Revenue for 2025 was $25.92B, with net income of $2.20B and an 11.38% net margin. Analyst consensus is a Buy with a $73.27 price target, and recent news highlights copper demand growth driven by AI and data centers.
FCX presents a positive outlook supported by robust copper demand trends and expansion projects, though rising production costs and a bearish technical picture pose near-term risks. The stock offers potential upside to the consensus target, but investors should monitor cost pressures and quarterly execution against expectations.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
